Full Text of PDF (710k)
Article in Japanese
Abstract
Review
The PDE4B inhibitor nerandomilast: a new therapeutic perspective for pulmonary fibrosis
Masataka Kuwanaa Yasuhiko Nishiokab Yasuhiro Kondohc
aDepartment of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine
bDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University
cDepartment of Respiratory Medicine and Allergy, Tosei General Hospital
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) and interstitial lung disease with progressive fibrosis (PF-ILD, recently referred to as PPF) are pulmonary fibrotic diseases with a poor prognosis. Although the treatment of various diseases, including respiratory diseases, using pan-phosphodiesterase 4 (PDE4) inhibitors has been investigated, their side effects, such as vomiting, prevent their use. Nerandomilast is a preferential inhibitor of PDE4B, which is involved in lung inflammation and fibrosis. It is a novel therapeutic agent with anti-inflammatory and anti-fibrotic effects that is expected to show improved tolerability. Here, we describe the clinical epidemiology of IPF and PF-ILD, the involvement of PDE4B in these pulmonary fibrotic diseases, and the clinical application of nerandomilast for treating them.
KEYWORDS
Idiopathic pulmonary fibrosis (IPF) Interstitial lung disease (ILD) Phosphodiesterase 4B (PDE4B) inhibitor
Received 26 Feb 2024 ／ Accepted 28 Mar 2024
AJRS, 13(4): 131-139, 2024
Copyright © The Japanese Respiratory Society All Rights Reserved.